Loteprednol etabonate (submicron) ophthalmic gel 0.38% dosed three times daily following cataract surgery: integrated analysis of two Phase III clinical studies

PURPOSE: To evaluate the efficacy and safety of a submicron formulation of loteprednol etabonate (LE) gel 0.38% instilled three times daily (TID) compared with vehicle for the treatment of inflammation and pain following cataract surgery with intraocular lens implantation, integrated across two mult...

Descripción completa

Detalles Bibliográficos
Autores principales: Fong, Raymond, Cavet, Megan E, DeCory, Heleen H, Vittitow, Jason L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6683659/
https://www.ncbi.nlm.nih.gov/pubmed/31447544
http://dx.doi.org/10.2147/OPTH.S210597

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6683659/
https://www.ncbi.nlm.nih.gov/pubmed/31447544
http://dx.doi.org/10.2147/OPTH.S210597

Ejemplares similares